vatalanib has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganslmayer, M; Herold, C; Zimmermann, A; Zopf, S | 1 |
| Fan, ST; Ho, DW; Lam, CT; Lau, CK; Liu, Y; Poon, RT; Tam, KH; Yang, ZF | 1 |
2 other study(ies) available for vatalanib and Experimental Hepatoma
| Article | Year |
|---|---|
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor; Tamoxifen; Tretinoin | 2011 |
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Endothelial Cells; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Inbred BUF; Vascular Endothelial Growth Factor A | 2006 |